153 related articles for article (PubMed ID: 37306724)
21. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
22. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotypes and Tumor Immune Microenvironment in Hepatocellular Carcinoma With Macrotrabecular Massive and Vessels Encapsulating Tumor Clusters.
Akiba J; Nakayama M; Kondo R; Kusano H; Ogasawara S; Mihara Y; Tanigawa M; Tsutsui K; Yano Y; Miyazaki D; Tokisawa S; Mitsuhashi T; Nomura H; Sanada S; Sakai H; Hisaka T; Yano H
In Vivo; 2024; 38(2):640-646. PubMed ID: 38418151
[TBL] [Abstract][Full Text] [Related]
24. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
[TBL] [Abstract][Full Text] [Related]
25. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
26. Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model.
Tischfield DJ; Gurevich A; Johnson O; Gatmaytan I; Nadolski GJ; Soulen MC; Kaplan DE; Furth E; Hunt SJ; Gade TPF
Radiology; 2022 Apr; 303(1):215-225. PubMed ID: 35014906
[TBL] [Abstract][Full Text] [Related]
27. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses.
Morisue R; Kojima M; Suzuki T; Nakatsura T; Ojima H; Watanabe R; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Ishii G; Gotohda N; Fujiwara T; Ochiai A
Int J Cancer; 2021 Aug; 149(3):546-560. PubMed ID: 33662146
[TBL] [Abstract][Full Text] [Related]
28. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
29. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
30. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
31. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
32. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
33. Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma.
Shigematsu Y; Amori G; Kanda H; Takahashi Y; Takazawa Y; Takeuchi K; Inamura K
Virchows Arch; 2022 Aug; 481(2):253-263. PubMed ID: 35459975
[TBL] [Abstract][Full Text] [Related]
34. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
[TBL] [Abstract][Full Text] [Related]
35. Intrahepatic inflammatory IgA
Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
[TBL] [Abstract][Full Text] [Related]
36. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
38. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma.
Yamashita S; Abe H; Yamashita H; Yagi K; Seto Y; Ushiku T
Histopathology; 2023 Aug; 83(2):264-275. PubMed ID: 37071391
[TBL] [Abstract][Full Text] [Related]
40. LAMTOR1 degrades MHC-II via the endocytic in hepatocellular carcinoma.
Wu B; Wang Q; Li B; Jiang M
Carcinogenesis; 2022 Dec; 43(11):1059-1070. PubMed ID: 36070764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]